ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Semaglutide

Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.

Drug pageSemaglutide: every studyMany companies study it; this page follows only the 163 they lead. All 451 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 11, 2018163 company-led studies, 15 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only1518 open or runningphase 4since Jul 11, 2018Jun 11, 2008Dec 13, 2026phase 1 · NCT07225816
CSPC Pharmaceutical Groupits history only20 open or runningphase 3since Nov 30, 2023Nov 30, 2023none ahead
Hangzhou Jiuyuan Gene Engineeringits history only21 open or runningphase 3since Feb 20, 2023Feb 20, 2023none ahead
Chengdu Brilliant Pharmaceutical11 open or runningphase 3since Mar 18, 2024Mar 18, 2024none ahead
Geropharmits history only10 open or runningphase 1since Jul 4, 2024Jul 4, 2024none ahead
Gila Therapeuticsits history only11 open or runningphase 4since Apr 17, 2026Apr 17, 2026May 2027phase 4 · NCT07728383
Korea United Pharm.its history only11 open or runningphase 1since Oct 28, 2026Oct 28, 2026Nov 1, 2027phase 1 · NCT07935200
Qilu Pharmaceuticalits history only11 open or runningphase 3since Jul 11, 2023Jul 11, 2023none ahead
Shanghai World Leader Pharmaceuticalits history only11 open or runningphase 1since Jan 28, 2026Jan 28, 2026none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Dec 13, 2024Dec 13, 2024none ahead

Also a collaborator on its studies: Celerion and Avance Clinical Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chengdu Brilliant Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2024First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT06339086 · 478 planned

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

The one study Chengdu Brilliant Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06339086Diabetes Mellitus, Type 23Not yet recruitingAug 30, 2025478

How it is read

Names in the registry

  • “semaglutide”, 83 entries
  • “Semaglutide”, 66 entries
  • “Oral semaglutide”, 11 entries
  • “Semaglutide 2.4 mg”, 3 entries
  • “Semaglutide J”, 3 entries

Codes read as this program: UI112, HD1916.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.